About
Focus
Pipeline
Patients
Investors
Company Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Governance
SEC Filings
Investor FAQs
Careers
About
Focus
Pipeline
Patients
Investors
Company Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Governance
SEC Filings
Investor FAQs
Careers
Society for Immunotherapy of Cancer (SITC) Annual Meeting
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2017
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T Cell Infiltration in Human Metastatic Melanoma
Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model
© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved.
Terms of Use
|
Privacy Policy
|
Consumer Health Data Privacy Policy